[go: up one dir, main page]

NO863803L - Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids). - Google Patents

Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).

Info

Publication number
NO863803L
NO863803L NO863803A NO863803A NO863803L NO 863803 L NO863803 L NO 863803L NO 863803 A NO863803 A NO 863803A NO 863803 A NO863803 A NO 863803A NO 863803 L NO863803 L NO 863803L
Authority
NO
Norway
Prior art keywords
vaccines
htlv
lav
acquired immunodeficiency
iii
Prior art date
Application number
NO863803A
Other languages
English (en)
Other versions
NO863803D0 (no
Inventor
Shiu-Lok Hu
Anthony F Purchio
Linda Madisen
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of NO863803D0 publication Critical patent/NO863803D0/no
Publication of NO863803L publication Critical patent/NO863803L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Rekombinantviruser som styrer uttrykkingen av peptider eller proteiner relatert til epitoper av LAV/HTLV-III, den etiologiske agensen som lympfadenopati-syndromet eller ervervet immunsvikt-syndrom, er beskrevet. Disse virusene kan prepareres som virale vaksiner eller i flerverdige vaksiner som beskytter mot LAV/HTLV-III- infeksjon. Antigeniske peptider og proteiner relatert til epitoper av LAV/HTLV-III er også beskrevet. Disse kan fremstilles ved å anvende rekombinante DNA-tek- nikker eller ved kjemisk syntese, og kan benyttes som immunogene underenhetsvaksiner eller som antigener i diagnostiske immunoanalyser.
NO863803A 1985-09-25 1986-09-24 Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids). NO863803L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (2)

Publication Number Publication Date
NO863803D0 NO863803D0 (no) 1986-09-24
NO863803L true NO863803L (no) 1987-03-26

Family

ID=27419757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO863803A NO863803L (no) 1985-09-25 1986-09-24 Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).

Country Status (22)

Country Link
CN (1) CN1020752C (no)
AT (1) ATA256786A (no)
CH (1) CH676247A5 (no)
DE (1) DE3690508T1 (no)
DK (1) DK455486A (no)
ES (2) ES2002490A6 (no)
FI (1) FI863848A7 (no)
FR (1) FR2587720A2 (no)
GB (1) GB2181435B (no)
GR (1) GR862412B (no)
HU (1) HU205780B (no)
IE (1) IE59314B1 (no)
IL (1) IL80073A (no)
IT (1) IT1195829B (no)
MY (1) MY103182A (no)
NL (1) NL8602422A (no)
NO (1) NO863803L (no)
NZ (1) NZ217645A (no)
PT (1) PT83434B (no)
SE (4) SE8604007L (no)
WO (1) WO1987002038A1 (no)
YU (1) YU46753B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0220234B1 (en) * 1985-04-08 1994-08-03 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
EP0260714B1 (en) * 1986-09-19 1994-06-29 Oncogen Limited Partnership The use of activated t-lymphocytes for preparing a pharmaceutical composition for the treatment of AIDS
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
JP2948823B2 (ja) * 1987-01-16 1999-09-13 アンステイテユ・パストウール ヒト免疫不全レトロウィルス（ｈｉｖ）関連抗原性ペプチド、そのウィルス感染の検出及びワクチンへの使用
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
DE68917520T2 (de) * 1988-05-06 1995-01-05 Ferropas Ag Verfahren und Systeme zur Herstellung von HIV-Antigenen.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ATE160377T1 (de) * 1989-04-18 1997-12-15 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
ES2198400T3 (es) * 1989-06-01 2004-02-01 Applied Biotechnology, Inc. Vector que codifica particulas virales no autopropagantes, defectuosas, auto-ensambladas.
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
AU672372B2 (en) * 1991-11-08 1996-10-03 Pharmacia & Upjohn Company Feline leukemia virus vaccines
AU688283B2 (en) 1992-09-29 1998-03-12 Novartis Ag Pulmonary delivery of active fragments of parathyroid hormone
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP2036541A1 (en) 1994-03-07 2009-03-18 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
CA2212682A1 (en) 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
DE59507617D1 (de) * 1995-09-06 2000-02-17 Schablonentechnik Kufstein Ag Verfahren zum Herstellen einer Siebdruckschablone
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (de) * 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
IE64006B1 (en) * 1984-10-18 1995-06-28 Pasteur Institut Antigens particulary envelope antigens of the virus of lymphadenopathies and of the acquired immune-deficiency syndrome and virus process for producing virus envelope antigens use of said antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
DE3588134T2 (de) * 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Also Published As

Publication number Publication date
SE9102976L (sv) 1993-04-15
GB2181435A (en) 1987-04-23
IL80073A0 (en) 1986-12-31
SE9102975L (sv) 1993-04-15
IT8667730A0 (it) 1986-09-24
FR2587720B2 (no) 1995-02-10
SE9102976D0 (sv) 1991-10-14
MY103182A (en) 1993-05-29
IE59314B1 (en) 1994-02-09
YU46753B (sh) 1994-05-10
SE8604007L (sv) 1987-03-26
CN1020752C (zh) 1993-05-19
DE3690508T1 (no) 1988-06-23
WO1987002038A1 (en) 1987-04-09
HUT42133A (en) 1987-06-29
HU205780B (en) 1992-06-29
CN86106632A (zh) 1987-05-13
SE8604007D0 (sv) 1986-09-23
FR2587720A2 (fr) 1987-03-27
IE862525L (en) 1987-03-25
NO863803D0 (no) 1986-09-24
GB2181435B (en) 1990-01-10
IL80073A (en) 1995-01-24
FI863848L (fi) 1987-03-26
DK455486A (da) 1987-03-26
GR862412B (en) 1987-01-23
FI863848A7 (fi) 1987-03-26
SE9102974L (sv) 1993-04-15
DK455486D0 (da) 1986-09-24
SE9102975D0 (sv) 1991-10-14
FI863848A0 (fi) 1986-09-24
CH676247A5 (no) 1990-12-28
GB8622987D0 (en) 1986-10-29
ES2002490A6 (es) 1988-08-16
IT1195829B (it) 1988-10-27
ATA256786A (de) 1995-05-15
PT83434B (pt) 1988-07-29
NL8602422A (nl) 1987-04-16
YU165486A (en) 1989-08-31
ES2006941A6 (es) 1989-05-16
SE9102974D0 (sv) 1991-10-14
NZ217645A (en) 1991-11-26
PT83434A (en) 1986-10-01

Similar Documents

Publication Publication Date Title
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
Pinter et al. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1
SE8701413D0 (sv) Expression and purification of an htlv-iii gag/env gene protein
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
DK33190A (da) Hiv-3 retrovirus og anvendelse heraf
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
DK1240186T3 (da) Forbedringer i eller relateret til immunrespons mod HIV
ATE109795T1 (de) Htlv-iii umhüllende peptiden.
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DK157186D0 (da) Ekspression af immunologisk aktive virale proteiner
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
DK245287A (da) Peptider relateret til htlv-iii virus, antistoffer mod disse peptider, vacciner til aktiv og passiv immunisering mod aids-virus og fremgangsmaade og udstyr til serologisk paavisning af aids virus
YOURNO et al. Nucleotide sequence analysis of the env gene of a new Zairian isolate of HIV-1
MATTHEWS et al. Prospects for development of a vaccine against HTLV-III-related disorders
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
NO971529L (no) Rekombinante proteiner av en Pakistani stamme av hepatitt E og deres anvendelse i diagnostiske metoder og vaksiner
SE9202934D0 (sv) Vacciner mot melanom
PT90800A (pt) Processo para a preparacao de antigenios precursores das glicoproteinas de involucro de um retrovirus humano hiv-2 e de antigenios que apresentem uma analogia imonulogiga com estes ultimos e sua aplicacao ao diagnostico
ZA88310B (en) Peptides capable of being recognized by antibodies induced against human immunodeficiency retrovirus(hiv-virus),their applications for diagnosis of infections caused by some of these viruses and,in case,to vaccination against aids
DK589586A (da) Ekspression og diagnostisk anvendelse af gag-kodede peptider, der er immunologisk reaktive med antistoffer til lav.
OA08716A (fr) Peptides susceptibles d'être reconnus par des anticorps induits contre des retrovirus d'immunodéficience humaine (virus HIV), leurs applications au diagnostic des infections dues à certains de ces virus et, le cas échéant, à la vaccination contre le sida.
PT86752A (pt) Procede pour la preparation de peptides susceptibles d:etre reconnus par des anticorps induits contre des retrovirus d:immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et le cas echeant a la vaccination contre le sida